TNYA
What one share of Tenaya Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease.
Tenaya Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.53 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.27 |
| Cash and investments | $0.35 |
| Book value | $0.31 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$39.50 | $10.04 | −$46.51 | — | −$67.19 |
| 2021 | — | −$4.10 | $1.42 | −$4.85 | — | — |
| 2022 | — | −$2.76 | $0.46 | −$2.79 | — | $3.64 |
| 2023 | — | −$1.68 | $0.02 | −$1.40 | — | $2.04 |
| 2024 | — | −$1.31 | $0.01 | −$1.08 | — | $1.07 |
| 2025 | — | −$0.59 | $0.00 | −$0.45 | — | $0.57 |